How cagrilintide suppresses appetite (in plain English)
- Cagrilintide is a long-acting amylin analogue that activates amylin receptors involved in satiety.
- It slows gastric emptying and strengthens “I’m full” signals to the brain’s appetite centres.
- People commonly report smaller portions, fewer cravings and less snacking when it works for them.
Cagrilintide targets a different pathway to GLP-1 medicines. Because the two mechanisms are complementary, researchers have explored a combination approach with semaglutide for stronger appetite suppression.
What the evidence says so far
Human trials suggest cagrilintide can reduce hunger and drive clinically meaningful weight loss:
- In a dose-ranging phase 2 trial (overweight/obesity), participants on cagrilintide reported lower hunger scores and achieved average weight reductions in the high single to low double digits over ~26–40 weeks, depending on dose.
- Early studies of the cagrilintide + semaglutide combination (often referred to as “CagriSema”) have shown larger reductions in body weight and appetite ratings than either medicine alone across ~32–52 weeks. Larger phase 3 programs are in progress.
Interpretation for appetite suppression: amylin-pathway signalling seems to enhance fullness and reduce energy intake. Combining it with GLP-1 signalling may further blunt hunger and cravings for some people.
How it compares with GLP-1 medicines for appetite
GLP-1s (e.g., semaglutide, tirzepatide which is GLP-1/GIP) and cagrilintide use different biological levers:
- GLP-1s: Reduce appetite, slow gastric emptying and improve glucose control.
- Cagrilintide: Amylin-receptor-driven satiety and gastric emptying effects, with distinct brain signalling.
Early data indicate the two can be additive for appetite control. If you’re weighing pathways, these pages can help:
Safety, side effects and who should avoid it
The most common reactions reported in trials were gastrointestinal. Appetite suppression can be strong—sometimes too strong—so careful titration and monitoring are important.
Common effects
- Nausea, vomiting
- Constipation or diarrhoea
- Abdominal discomfort, bloating, pronounced fullness
- Dizziness, headache, injection-site reactions
Less common but important
- Dehydration from persistent vomiting/diarrhoea
- Gallbladder issues have been observed across appetite/weight-loss drug classes; report upper-right abdominal pain
- Hypoglycaemia risk can increase if combined with insulin or sulfonylureas
Who may need extra caution or avoidance
- People with significant gastrointestinal disease (e.g., gastroparesis)
- History of pancreatitis—seek medical advice before any appetite/weight-loss agent
- Pregnancy or breastfeeding—weight-loss agents are generally avoided
Seek urgent care for severe abdominal pain, persistent vomiting, signs of dehydration, or suspected low blood sugar.
Dosing status and how it’s studied
Cagrilintide has been studied as a once-weekly subcutaneous injection with gradual dose escalation to improve tolerability. Dose ranges assessed in trials have spanned low to higher milligram strengths over time. Because it is investigational, dosing should only be considered within approved research protocols or compliant unapproved-use pathways under a doctor’s supervision.
Is cagrilintide available in Australia?
As of now, cagrilintide is not registered on the Australian Register of Therapeutic Goods (ARTG). This means:
- Routine pharmacy access is not available.
- Legitimate use is generally limited to clinical trials or specific unapproved-use pathways (e.g., Special Access Scheme or Authorised Prescriber) at a clinician’s discretion and with informed consent.
- Buying “research” versions online carries quality, legal and safety risks. Be wary of counterfeit or mislabelled products.
Who might benefit from cagrilintide’s appetite effects?
Possibly helpful for
- Adults with overweight or obesity who experience persistent hunger, frequent snacking or large portion sizes
- People who saw partial appetite benefit on GLP-1 therapy and are exploring different or complementary satiety pathways (research/clinician-supervised contexts only)
Might not be suitable for
- Those with significant gastrointestinal motility issues
- People unable to tolerate early GI side effects or who cannot maintain hydration/nutrition during titration
- Anyone seeking to self-source unapproved products without medical oversight
Frequently asked questions
How quickly does appetite suppression start?
In trials, many participants noticed reduced hunger during the titration phase, with fuller effects emerging over several weeks as doses stabilised.
Is the combination with semaglutide (CagriSema) stronger for appetite?
Early studies suggest greater appetite reduction and weight loss with the combination versus either alone, but it remains investigational pending full phase 3 data and regulatory decisions.
Will I need a special diet?
Most trials used general healthy eating guidance. Because appetite can drop sharply, clinicians emphasise protein intake, hydration and micronutrient quality to maintain lean mass and wellbeing.
Can cagrilintide be used if I’m on diabetes medications?
Only under medical supervision. Appetite and glucose changes can alter medication needs, especially with insulin or sulfonylureas due to hypoglycaemia risk.
What happens when treatment stops?
As with other appetite-targeting therapies, hunger can return and weight regain is possible. Long-term lifestyle strategies and follow-up care are important.
Is this medical advice?
No. This page is general information only. Speak with a qualified health professional for personal advice.
Final takeaway
Cagrilintide engages the amylin satiety pathway to reduce hunger and meal size. Human studies show meaningful appetite and weight effects, and early combination research with semaglutide looks promising. It is not currently approved in Australia; any use should be within compliant pathways and with clinical oversight to manage side effects and nutrition.
Have questions about cagrilintide and appetite?
Send a message and a clinician-aligned team will respond. This is general guidance only and not a substitute for medical advice.
We respect your privacy and only use your details to respond to your enquiry.